Wangwen Xiao
Overview
Explore the profile of Wangwen Xiao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang C, Xiao W, Wang R, Hu Y, Yi K, Sun X, et al.
Oncol Lett
. 2023 Jul;
26(2):328.
PMID: 37415635
The establishment of self-organizing 'mini-gut' organoid models has brought about a significant breakthrough in biomedical research. Patient-derived tumor organoids have emerged as valuable tools for preclinical studies, offering the retention...
2.
Zhang W, Yang C, Hu Y, Yi K, Xiao W, Xu X, et al.
Sci Rep
. 2023 Feb;
13(1):2409.
PMID: 36765148
Liver hepatocellular carcinoma (LIHC) is one of the most common malignancies and places a heavy burden on patients worldwide. HAUS augmin-like complex subunit 5 (HAUS5) is involved in the occurrence...
3.
Fang X, Liu Y, Xiao W, Zhao N, Zhu C, Yu D, et al.
Acta Biochim Biophys Sin (Shanghai)
. 2021 Jun;
53(8):1065-1075.
PMID: 34128989
The solute carrier (SLC) superfamily genes encode more than 300 members that are responsible for the transmembrane transportation of many essential endogenous and exogenous compounds ranging from nutrients to drugs....
4.
Zhang Y, Teng Y, Xiao W, Xu B, Zhao Y, Li W, et al.
Mol Ther Nucleic Acids
. 2020 Nov;
22:900-909.
PMID: 33251041
Recently, the US Food and Drug Administration (FDA) approved the first small interfering RNA (siRNA) drug, marking a significant milestone in the therapeutic use of RNA interference (RNAi) technology. However,...